Chondrosarcoma is a family of cartilage-producing bone cancers and the third most common primary bone sarcoma. Most chondrosarcomas grow slowly, metastasise in only 15–25% of cases and are primarily treated by surgery with the goal of clear margins and lasting cure.
Chondrosarcomas arise from cartilage cells in bone. They typically present as a slow-growing, painful mass and behave very differently from the other bone sarcomas — most do not respond to chemotherapy or radiotherapy, making complete surgical removal the key to cure.
Aching that lasts months — often the only early symptom.
A previously stable lump that suddenly starts enlarging.
Pain developing in an enchondroma or osteochondroma needs review.
Deep, vague pain in the pelvis or shoulder that does not settle.
The chondrosarcoma family includes several subtypes that look, behave and respond to treatment differently. Subtype is decided by an experienced bone-tumour pathologist.
The commonest form — central (within bone), peripheral (from bone surface) or juxtacortical.
High-grade and aggressive — a low-grade cartilage tumour with an abrupt high-grade non-cartilaginous component.
High-grade variant of young adults — chemotherapy-responsive with up to 89% 10-year survival in multimodal therapy.
Low-grade — typically affects the ends of long bones (epiphysis).
Tumour grade is the single most important factor determining treatment and survival.
Rarely metastasises (<5%). Often managed with extended curettage.
Wide surgical excision with clear margins.
Aggressive — wide excision and multidisciplinary planning.
Most aggressive — chemotherapy of limited benefit.
Imaging followed by a planned biopsy at a specialist centre. An improperly placed biopsy can compromise future limb salvage.
Show characteristic cartilage 'rings and arcs' calcification with endosteal scalloping or cortical destruction.
Defines tumour extent within bone and soft tissue — essential for surgical planning.
Assesses metabolic activity and detects metastases. Can occasionally avoid biopsy and guide treatment.
Confirms diagnosis — sometimes PET-CT guided to sample the most active area for accurate grading.
The approach is tailored to grade, location and subtype. Most cures are achieved by careful surgery with adequate margins.
For Grade I / Atypical Cartilaginous Tumours of the appendicular skeleton.
For pelvic, spinal and higher-grade tumours — the primary curative procedure.
Conventional chondrosarcoma is generally resistant to chemotherapy.
Slow-growing tumours respond poorly, but radiotherapy is valuable in selected scenarios.
Limb- and function-preserving surgery for chondrosarcoma in some of the most challenging anatomical regions.
Approach to a chondrosarcoma involving the pelvis — wide resection and reconstruction planning in a complex anatomical region.
Limb- and joint-preserving surgery for chondrosarcoma involving the hip bone with reconstructive options to restore function.
Wide excision of a pelvic chondrosarcoma where planned pseudoarthrosis (no bony reconstruction) provides excellent functional outcome.
A 45-year-old teacher noticed arm pain for 6 months. X-rays showed a cartilage tumour in the upper arm bone; biopsy confirmed Grade I chondrosarcoma. He underwent extended curettage with cement filling and returned to full activities within 3 months. Five years later he remains cancer-free with excellent arm function.
A 55-year-old homemaker developed severe hip pain and a rapidly growing mass. MRI revealed a large pelvic tumour with soft tissue extension; biopsy confirmed dedifferentiated chondrosarcoma. She underwent extensive pelvic resection with reconstruction followed by chemotherapy. Despite the aggressive disease, multimodal care provided meaningful disease control and ongoing surveillance.
Long-term surveillance is essential — chondrosarcoma is famous for late recurrences, sometimes years after the original surgery.
